Traditional scientific wisdom holds that heart attacks originate from severe blockages of the artery created by atherosclerosis, the progressive build up of plaque in the coronary arteries. Recent research indicates, however, that certain kinds of "vulnerable plaque" may trigger acute coronary events, creating demand for new diagnostic tools to identify and characterize the plaque and new treatments. The field is moving at a dizzying pace and is beginning to attract a handful of start-ups and venture capitalists; these see a huge opportunity, but also recognize the challenges inherent in changing entrenched approaches to treatment.
By Wendy Diller
Traditional scientific wisdom holds that heart attacks originate from severe blockages created by atherosclerosis, the progressive build-up of plaque in...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.
The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.
The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.
Despite near-term cost pressures, Intuitive Surgical is expanding manufacturing and R&D in North America and Europe to meet demand for Ion, X and Xi systems.
Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.
